SCHEMBL1618374

SCHEMBL1618374

COc1cc(-c2noc(C)n2)c(C(O)C(=O)NC(C)(C)C)cc1OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
SMPD1 P17405 2/20 0.43
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
F2 P00734 2/20 0.40
PRSS1 P07477 2/20 0.40
F7 P08709 2/20 0.40
CTSD P07339 1/20 0.40
F10 P00742 1/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SRD5A1 P18405 2/20 0.39
SRD5A2 P31213 2/20 0.39
POLB P06746 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8042183 0.86 SMPD1 (0.40) HPGDKDM4ESMPD1HDAC1HDAC8
SCHEMBL1617935 0.86 ALDH1A1 (0.44) HPGDALDH1A1SMPD1HDAC1HDAC8
SCHEMBL1618222 0.85 SMN1; SMN2 (0.45) HPGDKDM4EALDH1A1SMPD1HDAC1
SCHEMBL12717238 0.84 HPGD (0.44) HPGDKDM4EALDH1A1SMPD1HDAC1
SCHEMBL1618194 0.83 SMPD1 (0.40) HPGDKDM4ESMPD1HDAC1HDAC8
SCHEMBL1618200 0.83 SMPD1 (0.40) HPGDKDM4ESMPD1HDAC1HDAC8
SCHEMBL12717188 0.81 LMNA (0.39) HPGDKDM4ESMPD1HDAC1HDAC8
SCHEMBL12717111 0.81 KDM4E (0.50) HPGDKDM4EALDH1A1SMPD1MAPT
SCHEMBL8035391 0.81 HCRTR1 (0.39) HPGDKDM4ESMPD1MAPTNPC1
SCHEMBL12717167 0.81 SMPD1 (0.39) HPGDKDM4ESMPD1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246338-B1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL (JP) 2013-11-20 EP disclosed
US-7923462-B2 Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-04-12 US disclosed
US-20100280083-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-11-04 US disclosed
EP-2246338-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION Kissei Pharmaceutical Co., Ltd. (JP) 2010-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280083-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION COMT, CYP2D6, CYP3A43 HPGD 964/4885KDM4E 614/4885ALDH1A1 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.